Recombinant Factor VIIa (rFVIIa) can be useful in the management of a patient with congenital Factor VII deficiency.
Factors affecting how to treat a Factor VII deficiency:
(1) bleeding into high risk areas (CNS, cardiothoracic, ophthalmic)
(2) severity of other bleeding
(3) cause of the bleeding (trauma or surgery vs spontaneous)
(4) Factor VII activity
(5) patient's tolerance to volume load
Factor VII Activity
Factor VII therapy until controlled
monitor patient closely, minimize risk for injury
Therapy is complicated due to the short half-life of factor VII (2-5 hours)
Therapy with fresh frozen plasma (FFP):
(1) initially 10-15 mL per kg
(2) maintenance 3-6 mL per kg every 6-8 hours until bleeding resolved
Therapy with rFVIIa:
(1) 20 micrograms per kg IV every 2 hours (roughly approximates one 1.2 mg vial).
(2) rFVIIa comes in 1.2, 2.4 and 4.8 mg vials.
Therapy with FFP and rFVIIa can be combined to meet the needs of the patient.
To read more or access our algorithms and calculators, please log in or register.
Specialty: Hematology Oncology, Clinical Laboratory, Clinical Pharmacology